Cell Death & Disease

Table 1 Sensitivity of 60 myeloma primary samples to BCL2 and MCL1 inhibitor combination.

From: Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

#	Characteristics of patient				% of cell death (MCL1i + BCL2i)
#	Age/sex	Disease	Status	% of PC	% of cell death (MCL1i + BCL2i)
1	58/F	MM	Diag	3%	78
2	70/F	MM	Diag	19%	85
3	73/M	MM	Diag	9%	88
4	59/M	MM	Diag	7%	93
5	70/M	MM	Diag	12%	97
6	65/M	MM	Diag	4%	99
7	72/M	MM	Rel	6%	70
8	62/M	MM	Rel	13%	89
9	71/M	MM	Rel	5%	92
10	61/F	MM	Rel	13%	94
11	45/F	MM	Rel	4%	96
12	53/M	MM	Rel	22%	97
13	69/M	MM	Rel	37%	98
14	69/F	MM	Rel	4%	100
15	61/M	MM	Diag	9%	84
16	59/M	MM	Diag	6%	95
17	74/M	MM	Diag	20%	98
18	55/M	MM	Diag	21%	99
19	56/M	MM	Diag	39%	99
20	76/M	MM	Diag	18%	99
21	65/M	MM	Rel	18%	57
22	65/F	MM	Rel	5%	63
23	58/M	MM	Rel	4%	84
24	61/F	MM	Rel	4%	89
25	66/F	sPCL	Rel	12%	97
26	83/F	MM	Rel	9%	97
27	62/F	MM	Rel	19%	98
28	60/M	MM	Rel	8%	100
29	70/F	MM	Rel	18%	100
30	76/M	MM	Diag	3%	9
31	88/F	MM	Diag	4%	38
32	82/F	MM	Diag	3%	41
33	73/F	MM	Diag	17%	50
34	55/F	MM	Diag	8%	51
35	66/F	MM	Diag	21%	53
36	71/F	MM	Diag	23%	59
37	56/F	MM	Diag	22%	73
38	67/F	MM	Diag	6%	82
39	66/M	MM	Diag	15%	89
40	54/F	MM	Diag	43%	94
41	58/F	sPCL	Rel	80%	0
42	60/F	MM	Rel	10%	11
43	83/M	MM	Rel	14%	12
44	81/F	sPCL	Rel	22%	22
45	63/F	MM	Rel	20%	33
46	81/M	MM	Rel	9%	45
47	72/M	MM	Rel	26%	53
48	70/M	MM	Rel	4%	56
49	76/M	MM	Rel	8%	59
50	78/M	MM	Rel	11%	60
51	72/M	MM	Rel	59%	66
52	63/F	MM	Rel	21%	71
53	70/M	sPCL	Rel	8%	71
54	65/M	MM	Rel	3%	72
55	78/M	MM	Rel	4%	80
56	74/F	MM	Rel	7%	80
57	64/M	sPCL	Rel	31%	88
58	86/F	MM	Rel	76%	88
59	82/M	sPCL	Rel	23%	91
60	76/M	MM	Rel	7%	99

The percentage of cell death induced by the BCL2 and MCL1 inhibitor combination (300 nM of venetoclax with 25 nM of S63845 or 2.5 μM of A1210477) was indicated. Patients have been ordered according to clustering defined in Fig. 2a: patients #1 to #14 were highly BCL2 dependent (red cluster); patients #15 to # 29 were highly MCL1 dependent (blue cluster) and patients #30 to # 60 were resistant or poorly sensitive to MCL1, BCL2, or both inhibitors (green cluster).
F female, M male, MM multiple myeloma, sPCL secondary plasma cell leukemia, Diag diagnosis, Rel relapse, PC plasma cells.

Back to article page

Search

Advanced search

Quick links